Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection

References

• Bellentani S, Miglioli L, Masutti F, et al. Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery. Microbes Infect 2000;2(14):1757-63
   PubMed Web of Science ®Google Scholar
• Craxi A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008;29(1-2):85-95
   PubMed Web of Science ®Google Scholar
• Zignego AL, Gragnani L, Giannini C, Laffi G. The hepatitis C virus infection as a systemic disease. Intern Emerg Med 2012;7(Suppl 3):S201-8
   PubMedGoogle Scholar
• Zignego AL, Macchia D, Monti M, et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. [see comments] J Hepatol 1992;15(3):382-6
   PubMed Web of Science ®Google Scholar
• Zignego AL, Giannini C, Monti M, Gragnani L. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 2007;39(Suppl 1):S38-45
   PubMedGoogle Scholar
• Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 1991;9(6):621-4
   PubMed Web of Science ®Google Scholar
• Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol 1994;88(2):392-4
   PubMed Web of Science ®Google Scholar
• Ferri C, Baicchi U, la Civita L, et al. Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. Eur J Clin Invest 1993;23(12):851-5
   PubMed Web of Science ®Google Scholar
• Ferri C, La Civita L, Longombardo G, et al. Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma. letter Clin Exp Rheumatol 1994;12(1):89-90
   PubMed Web of Science ®Google Scholar
• Ferri C, La Civita L, Caracciolo F, Zignego AL. Non-Hodgkin’s lymphoma: possible role of hepatitis C virus. letter Jama 1994;272(5):355-6
   PubMed Web of Science ®Google Scholar
• La Civita L, Zignego AL, Monti M, et al. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum 1995;38(12):1859-60
   PubMedGoogle Scholar
• Ferri C, La Civita L, Caracciolo F, et al. Hepatitis C virus and lymphoproliferative disorders. Blood 1996;88(12):4730-1
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ferri C, Giannini C, et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non- Hodgkin’s lymphoma: evidence for a pathogenetic role. Arch Virol 1997;142(3):545-55
   PubMed Web of Science ®Google Scholar
• Ferri C SM, Saadoun D, Cacoub P. Cryoglobulinemia and hepatitis C virus. In: Bijsma J, editor. EULAR compendium on rheumatic diseases, 2012. BMJ Publishing Group, London; 2012.pp. 1042-71
   Google Scholar
• Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007;13(17):2467-78
   PubMed Web of Science ®Google Scholar
• Ferri C, La Civita L, Longombardo G, et al. Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. Lupus 1998;7(4):275-9
   PubMed Web of Science ®Google Scholar
• Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol 2012;2012:980942
   PubMedGoogle Scholar
• AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2014. Available from: http://www.hcvguidelines.org
   Google Scholar
• Sansonno D, De Vita S, Iacobelli AR, et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998;160(7):3594-601
   PubMed Web of Science ®Google Scholar
• Racanelli V, Sansonno D, Piccoli C, et al. Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 2001;167(1):21-9
   PubMed Web of Science ®Google Scholar
• Agnello V, Zhang QX, Abel G, Knight GB. The association of hepatitis C virus infection with monoclonal rheumatoid factors bearing the WA cross-idiotype: implications for the etiopathogenesis and therapy of mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13(Suppl 13):S101-4
   PubMed Web of Science ®Google Scholar
• Knight GB, Gao L, Gragnani L, et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum 2010;62(7):2152-9
   PubMedGoogle Scholar
• Sansonno D, Lauletta G, De Re V, et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 2004;34(1):126-36
   PubMed Web of Science ®Google Scholar
• De Re V, De Vita S, Marzotto A, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 2000;96(10):3578-84
   PubMed Web of Science ®Google Scholar
• Quinn ER, Chan CH, Hadlock KG, et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001;98(13):3745-9
   PubMed Web of Science ®Google Scholar
• De Re V, Sansonno D, Simula MP, et al. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia 2006;20(6):1145-54
   PubMed Web of Science ®Google Scholar
• Hu YW, Rocheleau L, Larke B, et al. Immunoglobulin mimicry by Hepatitis C Virus envelope protein E2. Virology 2005;332(2):538-49
   PubMed Web of Science ®Google Scholar
• Ferri S, Dal Pero F, Bortoletto G, et al. Detailed analysis of the E2-IgM complex in hepatitis C-related type II mixed cryoglobulinaemia. J Viral Hepat 2006;13(3):166-76
   PubMed Web of Science ®Google Scholar
• Ng PP, Kuo CC, Wang S, et al. B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. Blood 2014;123(10):1512-15
   PubMed Web of Science ®Google Scholar
• Sagaert X, Van Cutsem E, De Hertogh G, et al. Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol 2010;7(6):336-46
   PubMed Web of Science ®Google Scholar
• Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998;282(5390):938-41
   PubMed Web of Science ®Google Scholar
• Rosa D, Saletti G, De Gregorio E, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005;102(51):18544-9
   PubMed Web of Science ®Google Scholar
• Machida K, Cheng KT, Pavio N, et al. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol 2005;79(13):8079-89
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Slobodin G, Kessel A, et al. Peripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infection. Clin Exp Immunol 2002;128(2):353-8
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Kessel A, Slobodin G, et al. Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection. J Virol 2003;77(19):10432-6
   PubMed Web of Science ®Google Scholar
• Toubi E, Kessel A, Peri R, et al. Enhanced apoptosis of peripheral CD5-negative B lymphocytes from chronically hepatitis C virus-infected patients: reversal after antiviral treatment. J Virol 2004;78(20):11379-84
   PubMed Web of Science ®Google Scholar
• Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 2004;101(12):4262-7
   PubMed Web of Science ®Google Scholar
• Ito M, Murakami K, Suzuki T, et al. Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol 2010;135(3):459-65
   PubMed Web of Science ®Google Scholar
• Zignego AL, De Carli M, Monti M, et al. Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. J Med Virol 1995;47(1):58-64
   PubMed Web of Science ®Google Scholar
• Ferri C, Monti M, La Civita L, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993;82(12):3701-4
   PubMed Web of Science ®Google Scholar
• Galli M, Zehender G, Monti G, et al. Hepatitis C virus RNA in the bone marrow of patients with mixed cryoglobulinemia and in subjects with noncryoglobulinemic chronic hepatitis type C. J Infect Dis 1995;171(3):672-5
   PubMed Web of Science ®Google Scholar
• Bronowicki JP, Loriot MA, Thiers V, et al. Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology 1998;28(1):211-18
   PubMed Web of Science ®Google Scholar
• Sung VM, Shimodaira S, Doughty AL, et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 2003;77(3):2134-46
   PubMed Web of Science ®Google Scholar
• Nakai M, Seya T, Matsumoto M, et al. The J6JFH1 strain of hepatitis C virus infects human B-cells with low replication efficacy. Viral Immunol 2014;27(6):285-94
   PubMed Web of Science ®Google Scholar
• Giannini C, Brechot C. Hepatitis C virus biology. Cell Death Differ 2003(10 Suppl 1):S27-38
   PubMedGoogle Scholar
• Russi S, Sansonno D, Mariggio MA, et al. Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia. Arthritis Res Ther 2014;16(2):R73
   PubMed Web of Science ®Google Scholar
• Alisi A, Giannini C, Spaziani A, et al. Hepatitis C virus core protein enhances B lymphocyte proliferation. Dig Liver Dis 2007;39(Suppl 1):S72-5
   PubMedGoogle Scholar
• Alisi A, Giannini C, Spaziani A, et al. Involvement of PI3K in HCV-related lymphoproliferative disorders. J Cell Physiol 2008;214(2):396-404
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Shibuya K, Yasui K, et al. Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. Comp Immunol Microbiol Infect Dis 2003;26(2):115-24
   PubMed Web of Science ®Google Scholar
• Machida K, Tsukiyama-Kohara K, Sekiguch S, et al. Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins. Gastroenterology 2009;137(1):285-96
   PubMed Web of Science ®Google Scholar
• Kasama Y, Sekiguchi S, Saito M, et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 2010;116(23):4926-33
   PubMed Web of Science ®Google Scholar
• Zignego AL, Giannelli F, Marrocchi ME, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 2000;31(2):474-9
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002;137:571-80
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Zuckerman T, Sahar D, et al. The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001;97(6):1555-9
   PubMed Web of Science ®Google Scholar
• Giannelli F, Moscarella S, Giannini C, et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003;102(4):1196-201
   PubMed Web of Science ®Google Scholar
• Giannini C, Giannelli F, Zignego A. Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology 2006;43(5):1166-7
   PubMed Web of Science ®Google Scholar
• Giannini C, Petrarca A, Monti M, et al. Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood 2008;111(5):2943-5
   PubMed Web of Science ®Google Scholar
• Goldberg-Bittman L, Kitay-Cohen Y, Hadari R, et al. Random aneuploidy in chronic hepatitis C patients. Cancer Genet Cytogenet 2008;180(1):20-3
   PubMedGoogle Scholar
• Machida K, Liu JC, McNamara G, et al. Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway. J Virol 2009;83(23):12590-600
   PubMed Web of Science ®Google Scholar
• Pozzato G, Burrone O, Baba K, et al. Ethnic difference in the prevalence of monoclonal B-cell proliferation in patients affected by hepatitis C virus chronic liver disease. J Hepatol 1999;30(6):990-4
   PubMed Web of Science ®Google Scholar
• Persico M, Capasso M, Persico E, et al. Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol 2006;45(6):779-85
   PubMed Web of Science ®Google Scholar
• Fabris M, Quartuccio L, Salvin S, et al. Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia. Ann Rheum Dis 2008;67(1):80-3
   PubMed Web of Science ®Google Scholar
• Farawela H, Khorshied M, Shaheen I, et al. The association between hepatitis C virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin’s lymphoma risk in Egypt. Infect Genet Evol 2012;12(6):1189-94
   PubMed Web of Science ®Google Scholar
• Giannini C, Gragnani L, Piluso A, et al. Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? Blood 2008;112(10):4353-4
   PubMed Web of Science ®Google Scholar
• Gragnani L, Piluso A, Giannini C, et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum 2011;63(5):1446-51
   PubMedGoogle Scholar
• Gragnani L, Fognani E, Piluso A, Zignego AL. Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? World J Gastroenterol 2013;19(47):8910-15
   PubMed Web of Science ®Google Scholar
• Piluso A, Giannini C, Fognani E, et al. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat 2013;20(4):e107-14
   PubMed Web of Science ®Google Scholar
• Sansonno D, Russi S, Serviddio G, et al. Interleukin 28B gene polymorphisms in hepatitis C virus-related cryoglobulinemic vasculitis. J Rheumatol 2014;41(1):91-8
   PubMed Web of Science ®Google Scholar
• Ossi E, Bordin MC, Businaro MA, et al. HLA expression in type II mixed cryoglobulinemia and chronic hepatitis C virus. Clin Exp Rheumatol 1995;13(Suppl 13):S91-3
   PubMedGoogle Scholar
• Congia M, Clemente MG, Dessi C, et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996;24(6):1338-41
   PubMed Web of Science ®Google Scholar
• Lenzi M, Frisoni M, Mantovani V, et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus- related mixed cryoglobulinemia. Blood 1998;91(6):2062-6
   PubMed Web of Science ®Google Scholar
• Amoroso A, Berrino M, Canale L, et al. Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglobulinemia type II after hepatitis C virus infection? J Hepatol 1998;29(1):36-44
   PubMed Web of Science ®Google Scholar
• De Re V, Caggiari L, Monti G, et al. HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin’s lymphoma is related to the type II mixed cryoglobulinemia. Tissue Antigens 2010;75(2):127-35
   PubMedGoogle Scholar
• Cacoub P, Renou C, Kerr G, et al. Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum 2001;44(9):2118-24
   PubMedGoogle Scholar
• Hwang SJ, Chu CW, Huang DF, et al. Genetic predispositions for the presence of cryoglobulinemia and serum autoantibodies in Chinese patients with chronic hepatitis C. Tissue Antigens 2002;59(1):31-7
   PubMedGoogle Scholar
• Zignego AL, Wojcik GL, Cacoub P, et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun 2014;15(7):500-5
   PubMed Web of Science ®Google Scholar
• Bouteloup M, Verney A, Rachinel N, et al. MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol 2012;156(2):279-81
   PubMed Web of Science ®Google Scholar
• Di Lisio L, Martinez N, Montes-Moreno S, et al. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 2012;120(9):1782-90
   PubMed Web of Science ®Google Scholar
• Peveling-Oberhag J, Crisman G, Schmidt A, et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 2012;26(7):1654-62
   PubMed Web of Science ®Google Scholar
• Fognani E, Giannini C, Piluso A, et al. Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. PLoS One 2013;8(5):e62965
   PubMed Web of Science ®Google Scholar
• Gragnani L, Fognani E, Piluso A, Zignego AL. Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26b. J Hepatol 2013;59(6):1362-3
   PubMed Web of Science ®Google Scholar
• Saadoun D, Bieche I, Maisonobe T, et al. Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum 2005;52(9):2917-25
   PubMedGoogle Scholar
• Feldmann G, Nischalke HD, Nattermann J, et al. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma. Clin Cancer Res 2006;12(15):4491-8
   PubMed Web of Science ®Google Scholar
• Sansonno D, Tucci FA, Troiani L, et al. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. Blood 2008;112(5):1620-7
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 2008;42(1):137-43
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008;103(10):2488-94
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Ferrari SM, et al. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. J Rheumatol 2010;37(1):91-7
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Ferrari SM, et al. High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-{gamma}. J Rheumatol 2011;38(9):1947-52
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinaemia are associated with circulating levels of IFN-gamma and TNF-alpha. Clin Exp Rheumatol 2012;30(6):864-70
   PubMed Web of Science ®Google Scholar
• Toubi E, Gordon S, Kessel A, et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006;27(2):134-9
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Fabris M. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both? Autoimmun Rev 2008;8(2):95-9
   PubMed Web of Science ®Google Scholar
• Novak AJ, Grote DM, Ziesmer SC, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006;24(6):983-7
   PubMed Web of Science ®Google Scholar
• Libra M, Indelicato M, De Re V, et al. Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. Cancer Biol Ther 2005;4(11):1192-4
   PubMed Web of Science ®Google Scholar
• Libra M, Mangano K, Anzaldi M, et al. Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol Rep 2006;15(5):1305-8
   PubMed Web of Science ®Google Scholar
• Ferri C, Antonelli A, Mascia MT, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007;39(Suppl 1):S13-21
   PubMedGoogle Scholar
• Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008;3:25
   PubMed Web of Science ®Google Scholar
• Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995;88(2):115-26
   PubMedGoogle Scholar
• Dammacco F, Sansonno D, Piccoli C, et al. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis 2000;20(2):143-57
   PubMed Web of Science ®Google Scholar
• Lenzi M, Johnson PJ, McFarlane IG, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet 1991;338(8762):277-80
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ferri C, Giannini C, et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996;124(1 Pt 1):31-4
   PubMed Web of Science ®Google Scholar
• De Re V, Caggiari L, Simula MP, et al. Role of the HLA class II: HCV-related disorders. Ann N Y Acad Sci 2007;1107:308-18
   PubMed Web of Science ®Google Scholar
• Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33(6):355-74
   PubMed Web of Science ®Google Scholar
• Lauletta G, Russi S, Conteduca V, et al. Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study. Medicine (Baltimore). 2013. [Epub ahead of print]
   Google Scholar
• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81
   PubMed Web of Science ®Google Scholar
• Knight GB, Agnello V, Bonagura V, et al. Human rheumatoid factor cross-idiotypes. IV. Studies on WA XId-positive IgM without rheumatoid factor activity provide evidence that the WA XId is not unique to rheumatoid factors and is distinct from the 17.109 and G6 XIds. J Exp Med 1993;178(6):1903-11
   PubMed Web of Science ®Google Scholar
• Ferri C, Antonelli A, Mascia MT, et al. B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007;7(2):114-20
   PubMed Web of Science ®Google Scholar
• Meltzer M, Franklin EC, Elias K, et al. Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966;40(6):837-56
   PubMed Web of Science ®Google Scholar
• De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011;70(7):1183-90
   PubMed Web of Science ®Google Scholar
• Monti G, Saccardo F. Emergency in cryoglobulinemic syndrome: what to do? Dig Liver Dis 2007;39(Suppl 1):S112-15
   PubMedGoogle Scholar
• Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993;81(5):1132-6
   PubMed Web of Science ®Google Scholar
• Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. see comments N Engl J Med 1994;330(11):751-6
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Utili R, Zampino R, et al. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. Eur J Gastroenterol Hepatol 1997;9(11):1067-72
   PubMed Web of Science ®Google Scholar
• Mazzaro C, Monti G, Saccardo F, et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol 2011;29(6):933-41
   PubMed Web of Science ®Google Scholar
• Gragnani L, Fognani E, Piluso A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology 2014. [Epub ahead of print]
   Google Scholar
• Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011;10(8):444-54
   PubMed Web of Science ®Google Scholar
• Gragnani L, Fabbrizzi A, Triboli E, et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis 2014;46(9):833-7
   PubMedGoogle Scholar
• Saadoun D, Resche Rigon M, Pol S, et al. Peg-IFNalphaRibavirin/Protease inhibitor combination in severe hepatitis C virus associated mixed cryoglobulinemia vasculitis. J Hepatol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101(10):3827-34
   PubMed Web of Science ®Google Scholar
• Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011;10(11):714-19
   PubMed Web of Science ®Google Scholar
• Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010;116(3):335-42
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Petrarca A, Mansutti E, et al. Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia. Clin Exp Rheumatol 2010;28(1 Suppl 57):84-7
   PubMed Web of Science ®Google Scholar
• Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011;11(1):48-55
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64(3):843-53
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116(3):326-34. quiz 504-325
   PubMed Web of Science ®Google Scholar
• Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116(3):343-53
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ferri C, Pileri SA, et al. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007;39(1):2-17
   PubMedGoogle Scholar
• Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 1999;31(2):369-76
   PubMed Web of Science ®Google Scholar
• Ferri C, Caracciolo F, La Civita L, et al. Hepatitis C virus infection and B-cell lymphomas. letter Eur J Cancer 1994;10:2.1591-2
   Google Scholar
• De Vita S, Sansonno D, Dolcetti R, et al. Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood 1995;86(5):1887-92
   PubMed Web of Science ®Google Scholar
• Luppi M, Grazia Ferrari M, Bonaccorsi G, et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia 1996;10(2):351-5
   PubMed Web of Science ®Google Scholar
• Ferri C, La Civita L, Monti M, et al. Chronic hepatitis C and B-cell non-Hodgkin’s lymphoma. QJM 1996;89(2):117-22
   PubMedGoogle Scholar
• Mazzaro C, Zagonel V, Monfardini S, et al. Hepatitis C virus and non-Hodgkin’s lymphomas. see comments Br J Haematol 1996;94(3):544-50
   PubMed Web of Science ®Google Scholar
• Pioltelli P, Zehender G, Monti G, et al.V and non-Hodgkin lymphoma. Lancet 1996;347(9001):624-5
   PubMed Web of Science ®Google Scholar
• Silvestri F, Pipan C, Barillari G, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996;87(10):4296-301
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997;127(6):423-8
   PubMed Web of Science ®Google Scholar
• Silvestri F, Barillari G, Fanin R, et al. Hepatitis C virus infection among cryoglobulinemic and non- cryoglobulinemic B-cell non-Hodgkin’s lymphomas. Haematologica 1997;82(3):314-17
   PubMed Web of Science ®Google Scholar
• Izumi T, Sasaki R, Tsunoda S, et al. B cell malignancy and hepatitis C virus infection. Leukemia 1997(Suppl 3):516-18
   PubMedGoogle Scholar
• Brind AM, Watson JP, Burt A, et al. Non-Hodgkin’s lymphoma and hepatitis C virus infection. Leuk Lymphoma 1996(1-2):27-130
   PubMed Web of Science ®Google Scholar
• Hanley J, Jarvis L, Simmonds P, et al. HCV and non-Hodgkin lymphoma. Lancet 1996;7(9011):339
   Google Scholar
• McColl MD, Singer IO, Tait RC, et al. The role of hepatitis C virus in the aetiology of non-Hodgkins lymphoma--a regional association? Leuk Lymphoma 1997(1-2):27-130
   PubMed Web of Science ®Google Scholar
• Ellenrieder V, Weidenbach H, Frickhofen N, et al. HCV and HGV in B-cell non-Hodgkin’s lymphoma. J Hepatol 1998;28(1):34-9
   PubMed Web of Science ®Google Scholar
• Collier JD, Zanke B, Moore M, et al. No association between hepatitis C and B-cell lymphoma. see comments Hepatology 1999;4:259-1261
   Google Scholar
• Hausfater P, Cacoub P, Rosenthal E, et al. Hepatitis C virus infection and lymphoproliferative diseases in France: a national study. The GERMIVIC Group. Am J Hematol 2000;64(2):107-11
   PubMed Web of Science ®Google Scholar
• Matsuo K, Kusano A, Sugumar A, et al. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95(9):745-52
   PubMed Web of Science ®Google Scholar
• De Vita S, Sacco C, Sansonno D, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 1997;90(2):776-82
   PubMed Web of Science ®Google Scholar
• Ferri C, Pileri S, Zignego AL. Hepatitis C virus infection and non-Hodgkin’s lymphoma. In: Geodert J, (NIH), NCI editors. Infectious causes of cancer. Targets for intervention. The Human Press inc; Totowa, New Jersey: 2000. pp. 349-68
   Google Scholar
• Luppi M, Longo G, Ferrari MG, et al. Clinico-pathological characterization of hepatitis C virus-related B- cell non-Hodgkin’s lymphomas without symptomatic cryoglobulinemia [see comments]. Ann Oncol 1998;9(5):495-8
   PubMed Web of Science ®Google Scholar
• Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin’s lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 2004;110(3):380-5
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6(4):451-8
   PubMed Web of Science ®Google Scholar
• Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003;102(3):996-9
   PubMed Web of Science ®Google Scholar
• Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998;129(4):94-298
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120(12):1034-41
   PubMed Web of Science ®Google Scholar
• Casato M, Mecucci C, Agnello V, et al. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood 2002;99(6):2259-61
   PubMed Web of Science ®Google Scholar
• Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005;105(1):74-6
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347(2):89-94
   PubMed Web of Science ®Google Scholar
• Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007;120(Suppl 12):1-39
   PubMed Web of Science ®Google Scholar
• Mazzaro C, De Re V, Spina M, et al. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 2009;145(2):255-7
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004;18(10):1711-16
   PubMed Web of Science ®Google Scholar
• Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23(3):468-73
   PubMed Web of Science ®Google Scholar
• Bauduer F. MALT non-Hodgkin’s lymphoma associated with hepatitis C virus infection treated by interferon alpha. Am J Hematol 1996;53(3):209
   PubMed Web of Science ®Google Scholar
• Caramaschi P, Biasi D, Carletto A, et al. [MALT lymphomas of the salivary glands. Review of the literature apropos of a case in a patient with hepatitis C virus infection]. Recenti Prog Med 1999;90(11):585-91
   PubMedGoogle Scholar
• Moccia F, Tognoni E, Boccaccio P. The relationship between splenic marginal zone B-cell lymphoma and chronic liver disease associated with hepatitis C virus infection. Ann Ital Med Int 1999;14(4):288-93
   PubMedGoogle Scholar
• Patriarca F, Silvestri F, Fanin R, et al. Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment. Br J Haematol 2001;112(2):370-2
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004;100(1):107-15
   PubMed Web of Science ®Google Scholar
• Pitini V, Arrigo C, Righi M, et al. Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol 2004;124(2):252-3
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Torello M. Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. J Clin Gastroenterol 2004;38(4):360-3
   PubMed Web of Science ®Google Scholar
• Svoboda J, Andreadis C, Downs LH, et al. Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma 2005;46(9):1365-8
   PubMed Web of Science ®Google Scholar
• Kanbay M, Selcuk H, Gur G, et al. Response to peginterferon treatment in hepatitis C virus-associated splenic lymphoma with villous lymphocytes. Am J Hematol 2006;81(4):304-5
   PubMed Web of Science ®Google Scholar
• Oda Y, Kou T, Watanabe M, et al. Regression of B-cell lymphoma of the liver with hepatitis C virus infection after treatment with pegylated interferon-alpha and ribavirin. Dig Dis Sci 2010;55(6):1791-3
   PubMed Web of Science ®Google Scholar
• Paulli M, Arcaini L, Lucioni M, et al. Subcutaneous ’lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol 2010;21(6):1189-95
   PubMed Web of Science ®Google Scholar
• Nunes J, Tato Marinho R, Raposo J, Velosa J. [Influence of hepatitis C virus replication on splenic lymphoma with villous lymphocytes]. Acta Med Port 2010;23(5):941-4
   PubMed Web of Science ®Google Scholar
• Pellicelli AM, Marignani M, Zoli V, et al. Hepatitis C virus-related B cell subtypes in non Hodgkin’s lymphoma. World J Hepatol 2011;3(11):278-84
   PubMedGoogle Scholar
• Mauro E, Pedata M, Ermacora A, Mazzaro C. An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin’s lymphoma previously treated with interferon. Blood Transfus 2012;10(1):101-3
   PubMed Web of Science ®Google Scholar
• Takahashi K, Nishida N, Kawabata H, et al. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012;51(19):2745-7
   PubMed Web of Science ®Google Scholar
• Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014;25(7):1404-10
   PubMed Web of Science ®Google Scholar
• La Mura V, De Renzo A, Perna F, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma. J Hepatol 2008;49(4):557-63
   PubMed Web of Science ®Google Scholar
• Musto P, Dell’Olio M, Carotenuto M, et al. Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? Blood 1996;88(2):752-4
   PubMed Web of Science ®Google Scholar
• Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010;116(24):5119-25
   PubMed Web of Science ®Google Scholar
• Marignani M, Mangone M, Cox MC, et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis 2011;43(2):139-42
   PubMedGoogle Scholar
• Zignego AL, Giannini C, Gragnani L, et al. Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. J Transl Med 2012;10:158
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Ferrari SM, et al. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 2009;5(1):26-34
   PubMedGoogle Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004;97(8):499-506
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007;17(5):447-51
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol 2002;20(5):693-6
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter 2013;164(4):e305-12
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206(4):469-77
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 2005;28(10):2548-50
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford) 2004;43(2):238-40
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Fallahi P, et al. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006;34(1-2):32-8
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fazzi P, Fallahi P, et al. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest 2006;130(2):526-32
   PubMed Web of Science ®Google Scholar
• Michitaka K, Durazzo M, Tillmann HL, et al. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994;106(6):1603-10
   PubMed Web of Science ®Google Scholar
• Lindgren S, Braun HB, Michel G, et al. Absence of LKM-1 antibody reactivity in autoimmune and hepatitis-C-related chronic liver disease in Sweden. Swedish Internal Medicine Liver club. Scand J Gastroenterol 1997;32(2):175-8
   PubMed Web of Science ®Google Scholar
• Dalekos GN, Makri E, Loges S, et al. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol 2002;14(1):35-42
   PubMed Web of Science ®Google Scholar
• Monti V, Aghemo A, Rumi MG, et al. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies. Antivir Ther 2005;10(6):715-20
   PubMed Web of Science ®Google Scholar